Khiron Life Sciences Corp. (KHRWF)
| Previous Close | 0.0201 |
| Open | 0.0201 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0201 - 0.0201 |
| 52 Week Range | 0.0201 - 0.0201 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Medical Cannabis Innovator Khiron Continues Global Expansion as Industry Leader Throughout Europe and Latin America
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) the global medical cannabis leader, continues expansion of the Khiron end-to-end solution throughout Latin America and Europe. Khiron's growth aligns with its mission to improve consumers' quality of life through its global network of medical cannabis treatments clinics.
- CNW Group
Khiron Announces Results of 2022 Annual General and Special Meeting
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Latin America and Europe, announces the results of its 2022 Annual General and Special Meeting of shareholders (the "Meeting") held on June 23, 2022.
- CNW Group
KHIRON LIFE SCIENCES ANNOUNCES CLOSING OF $4.6 MILLION OVERNIGHT BROKERED OFFERING INCLUDING FULL EXERCISE OF OVER-ALLOTMENT OPTION
Khiron Life Sciences Corp. ("Khiron" or, the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), is pleased to announce that it has closed today its previously announced underwritten overnight public offering of units of the Company ("Units"), including the exercise in full of the over- allotment option (the "Offering").
